ClinicalTrials.gg
CompletedNCT00364871Updated Apr 22, 2008

Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity

A Phase 2 interventional study of naltrexone and bupropion SR in Obesity, sponsored by Orexigen Therapeutics, Inc. Completed at 7 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2008-04-22.

Sponsored by Orexigen Therapeutics, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
410
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing naltrexone in Obesity — 4 open to participants now, 4 under way, none of them phase 3. Naltrexone · Obesity.

Enrollment
6th of 23
410 · median 67
Started
2005
the only one that year
Phase 2
5 of 23
none open now
Registered
1st of 23
by date
Lead sponsor
10 of 23
Orexigen Therapeutics, Inc

Among the 23 studies testing naltrexone in Obesity, this one is the 6th largest by enrollment, is the only one that started in 2005, is one of 5 in phase 2, and was the 1st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 23 studies testing naltrexone in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About naltrexone

Naltrexone: first FDA approval 1984 (REVIA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing naltrexone in Obesity, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of 3 combinations of naltrexone and bupropion SR compared to naltrexone alone, bupropion SR alone or placebo.

Read the detailed description

A completed proof of concept study, OT-101 (Data on File, Orexigen Therapeutics, 2005), demonstrated that a combination of 300 mg bupropion SR and 50 mg naltrexone was associated with greater weight loss than bupropion SR alone, naltrexone alone, or placebo in subjects with uncomplicated obesity.

The hypothesis for the current trial is that by adjusting the doses and titration schedules of bupropion SR and naltrexone greater efficacy and improved tolerability can be achieved. In this trial, a higher dose of bupropion and 2 lower doses of naltrexone than utilized in the previous trial (OT-101) will be evaluated. The doses of both drugs will be titrated over 4 weeks and administered twice a day. There are 2 cohorts. At each site, cohort 2 recruitment began as soon as cohort 1 enrollment was completed. Cohort 1 treatment groups are (60 per group):

  • Group 1: Bupropion SR (400 mg/day) plus Naltrexone (48 mg/day)
  • Group 2: Bupropion SR (400 mg/day) plus Naltrexone (16 mg/day)
  • Group 3: Bupropion SR (400 mg/day) plus N-Placebo
  • Group 4: B-placebo plus Naltrexone (48 mg/day)
  • Group 5: B-Placebo plus N-Placebo

Cohort treatment 2 Groups are:

  • Group 6: B-Placebo plus N-Placebo (n=20)
  • Group 7: Bupropion SR (400 mg/day) plus Naltrexone (32 mg/day)(n=60)
03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Obesity
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female and male subjects, 18 to 60 years of age
  • Have (BMI) of 30 to 40 kg/m2
  • Free from illness or disease as determined by medical history and physical examination
  • Non-smoker and no use of tobacco or nicotine products for at least 6 months prior to baseline
  • Normotensive (systolic \<140 mm Hg; diastolic \<90 mm Hg). Anti-hypertensive medications are allowed with the exception of adrenergic blockers, beta-blockers and clonidine. Medical regimen must be stable for at least 6 weeks
  • LDL cholesterol \< 190 mg/dL and triglycerides \< 400 mg/dL. Medications for treatment of dyslipidemia are allowed as long as medical regimen has been stable for at least 6 weeks
  • No clinically significant abnormality of serum albumin, blood urea nitrogen, creatinine, calcium and phosphorus
  • , and AST within 1.5 x
  • No clinically significant abnormality of hematocrit, white blood cell count, white cell differential, or
  • Fasting glucose less than 140 mg/dL on no hypoglycemic agents
  • No clinically significant abnormality on urinalysis
  • TSH within 1.5 x ULN, normal T3, if TSH below lower limit of normal
  • Negative serum pregnancy test in women with intact uterus
  • Score \< 11 for depression and score \< 11 for anxiety on Hospital Anxiety and Depression (HAD) Scale
  • : no clinically significant abnormality
  • Score of zero on the Mood Assessment questionnaire and a response of "No" to the Bipolar Disorder Questions
  • If female with , must be non-lactating and agree to use effective throughout the study period and 30 days after discontinuation of study drugs
  • Able to comply with all required study procedures and schedule
  • Willing and able to give written

Exclusion criteria

Exclusion Criteria:

  • Obesity of known endocrine origin (e.g., untreated hypothyroidism, Cushing's syndrome)
  • Serious medical condition or medical condition that limits participation in the prescribed exercise program: (e.g. unstable cardiovascular disease including congestive heart failure, angina pectoris, and myocardial infarction; stroke; claudication; acute limb ischemia; acute renal or hepatic disorder; renal, hepatic or respiratory insufficiency)
  • Active or history of malignancy (other than non-melanoma skin cancer or surgically cured cervical cancer) within 5 years of enrollment
  • Serious psychiatric condition (e.g., any history of bipolar disorder, psychosis, suicidal attempt or post-partum depression; a history of major depression, suicidal ideation or antidepressant use within 1 year)
  • Type I or Type II diabetes mellitus requiring pharmacotherapy
  • Excluded concomitant medications: anorectic agents; weight loss agents; dietary supplements to promote muscle building, enhance mood, or reduce appetite; adrenergic blockers; beta blockers; anti-psychotic agents; clonidine; theophylline; cimetidine; oral ; anti-depressant; topiramate; Depo-Provera®, smoking cessation agents; frequent, known use of opioid or opioid-like analgesics
  • History of surgical intervention for obesity
  • History of seizure disorder or predisposition to seizures (e.g., history of cerebrovascular accident, significant head trauma, brain surgery, skull fracture, subdural hematoma, or febrile seizures)
  • History of bulimia or anorexia nervosa
  • History of drug or alcohol abuse within 5 years
  • History of treatment with bupropion, or naltrexone within 12 months
  • History of to bupropion, or naltrexone
  • Use of drugs, herbs, or dietary supplements known to significantly affect body weight within one month of baseline
  • Use of drug, device or procedure within 90 days
  • Participation in any previous clinical trial conducted by Orexigen Therapeutics
  • Any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in this study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
410 participants (actual)

Study arms

  • Experimental
    1

    Bupropion SR (400 mg/day) plus Naltrexone (48 mg/day)

    Drug: naltrexone and bupropion SR

  • Experimental
    2

    Bupropion SR (400 mg/day) plus Naltrexone (16 mg/day)

    Drug: naltrexone and bupropion SR

  • Active comparator
    3

    Bupropion SR (400 mg/day)

    Drug: naltrexone and bupropion SR

  • Active comparator
    4

    Naltrexone (48 mg/day)

    Drug: naltrexone and bupropion SR

  • Placebo comparator
    5

    B-Placebo plus N-Placebo

    Drug: naltrexone and bupropion SR

  • Placebo comparator
    6

    B-Placebo plus N-Placebo

    Drug: naltrexone and bupropion SR

  • Experimental
    7

    Bupropion SR (400 mg/day) plus Naltrexone (32 mg/day)

    Drug: naltrexone and bupropion SR

Interventions

  • Drugnaltrexone and bupropion SR

    Drug pages: Naltrexone · Bupropion

    naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day

06

What researchers measure

Primary outcomes

  1. Percentage change in total body weight

    Time frame: baseline to week 24

07

Study locations

7 sites
  • Scripps Clinic Del mar
    San Diego, California 92130, United States
  • CSRA Partners in Health, Inc
    Augusta, Georgia 30909, United States
  • UK Clinical Research Organization
    Lexington, Kentucky 40536, United States
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
  • Center for Nutrition and Preventive Medicine
    Charlotte, North Carolina 28211, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • MUSC Weight Management Center
    Charleston, South Carolina 29425, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of Mar 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2006
First posted
Aug 16, 2006
Start
Apr 2005
Primary completionActual
Mar 2007
CompletionActual
Mar 2007
Last update
Apr 22, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00364871
Lead sponsor
Orexigen Therapeutics, Inc
First posted
Aug 16, 2006
Start date
Apr 2005
Primary completion
Mar 2007
Completion
Mar 2007
Last update
Apr 22, 2008

Study contacts

Frank Greenway, MD
principal investigator · Pennington Biomedical Research Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naltrexone · Bupropion

Start the discussion